Highlights Compugen Ltd. TEL AVIV STOCK EXCHANGE

Equities

CGEN

IL0010852080

Delayed TEL AVIV STOCK EXCHANGE Other stock markets 01:26:52 07/07/2024 pm IST			5-day change	1st Jan Change
581.1 ^ILa	-8.70%		-9.47%	-15.54%

27/06	Transcript : Compugen Ltd. - Special Call
30/05	Compugen Ltd. to Receive Milestone Payment from Astrazeneca Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Compugen Ltd. to Receive Milestone Payment from Astrazeneca Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig	30/05	CI
Earnings Flash (CGEN) COMPUGEN Reports Q1 Revenue $2.6M, vs. Street Est of $1.2M	20/05	MT
Compugen Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	20/05	CI
Earnings Flash (CGEN) COMPUGEN Reports Q4 Revenue $33.5M	05/03	MT
Earnings Flash (CGEN) COMPUGEN Posts Q4 EPS $0.11	05/03	MT
Earnings Flash (CW9) COMPUGEN Posts Q4 EPS $0.11	05/03	MT
Compugen Ltd. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	05/03	CI
Exchange-Traded Funds, US Equities Rise Pre-Bell Tuesday as Investors Continue to Hope for Federal Reserve Rate Cuts Soon	19/12	MT
Gilead Sciences, Compugen Sign Exclusive Licensing Deal for Pre-Clinical Immunotherapy Program; Compugen Shares Soar	19/12	MT
Compugen Will Be Eligible to Receive $10 Million Milestone Payment Upon Dosing of First Patient in Astrazeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer	19/12	CI
Gilead Sciences, Inc. and Compugen Ltd. Announce Exclusive License Agreement for Novel Pre-Clinical Immunotherapy Program	19/12	CI
Compugen Gets Nasdaq Non-Compliance Notice on Minimum Bid Price Rule	04/11	MT
Compugen Ltd. Announces to Present New Data At Sitc 2023 Suggesting Leading Edge of Anti-Il18 Binding Protein Antibody, Com503, in Treating Cancer	31/23/31	CI
Compugen Gets Japanese Patent for Cancer Combination Therapy	02/23/02	MT
Compugen Expands Intellectual Property with New Japanese Patent for the Triple Combination of Anti-PVRIG, TIGIT and PD-1 Antibody for the Treatment of Cancer	02/23/02	CI
Compugen Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	07/23/07	CI
Compugen Says European Patent Office Rules in Favor of Maintaining Claims to Patent on Cancer Treatment	17/23/17	MT
Compugen Wins on PVRIG European Patent Opposition Pursued by GSK and a Third Party	17/23/17	CI
Compugen Ltd. Doses First Patient in Triple Immunotherapy Combination COM701, COM902 and Pembrolizumab Platinum Resistant Ovarian Cancer Proof-Of-Concept Study	22/23/22	CI
Compugen Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/23/15	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Compugen Ltd. TEL AVIV STOCK EXCHANGE

Equities

CGEN

IL0010852080

Highlights

Filters